AbbVie Financial Statements From 2010 to 2024

ABBV Stock  USD 164.66  0.41  0.25%   
AbbVie financial statements provide useful quarterly and yearly information to potential AbbVie Inc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on AbbVie financial statements helps investors assess AbbVie's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting AbbVie's valuation are summarized below:
Gross Profit
41.5 B
Profit Margin
0.0895
Market Capitalization
287.8 B
Enterprise Value Revenue
6.1473
Revenue
54.3 B
There are over one hundred nineteen available fundamental signals for AbbVie Inc, which can be analyzed over time and compared to other ratios. All traders should should validate AbbVie's prevailing fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable.

AbbVie Total Revenue

33.85 Billion

Check AbbVie financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AbbVie main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.1 B, Interest Expense of 1.1 B or Selling General Administrative of 8 B, as well as many exotic indicators such as Price To Sales Ratio of 3.39, Dividend Yield of 0.0289 or PTB Ratio of 17.19. AbbVie financial statements analysis is a perfect complement when working with AbbVie Valuation or Volatility modules.
  
This module can also supplement AbbVie's financial leverage analysis and stock options assessment as well as various AbbVie Technical models . Check out the analysis of AbbVie Correlation against competitors.

AbbVie Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding1.8 B1.8 B1.6 B
Slightly volatile
Total Assets81.2 B134.7 B74.3 B
Slightly volatile
Other Current Liabilities32.2 B30.6 B12.9 B
Slightly volatile
Total Current Liabilities39.7 B37.8 B18.4 B
Slightly volatile
Other Liabilities38.3 B36.5 B17 B
Slightly volatile
Property Plant And Equipment Net3.6 BB3.3 B
Slightly volatile
Accounts Payable3.9 B3.7 B1.8 B
Slightly volatile
Cash10.5 B12.8 B9.6 B
Slightly volatile
Non Current Assets Total57.7 B101.7 B52.8 B
Slightly volatile
Other Assets5.8 B5.6 B2.5 B
Slightly volatile
Cash And Short Term Investments11 B12.8 B10.1 B
Slightly volatile
Net Receivables6.8 B11.2 B6.3 B
Slightly volatile
Good Will18.6 B32.3 B17 B
Slightly volatile
Liabilities And Stockholders Equity81.2 B134.7 B74.3 B
Slightly volatile
Non Current Liabilities Total55.5 B86.5 B50.8 B
Slightly volatile
Inventory2.2 B4.1 BB
Slightly volatile
Other Current Assets3.5 B4.9 B3.2 B
Slightly volatile
Total Liabilities74.1 B124.3 B67.8 B
Slightly volatile
Property Plant And Equipment Gross12.2 B11.6 B5.1 B
Slightly volatile
Total Current Assets23.5 B33 B21.5 B
Slightly volatile
Intangible Assets32.2 B55.6 B29.5 B
Slightly volatile
Property Plant Equipment3.4 B5.7 B3.3 B
Slightly volatile
Long Term Debt41.2 B52.2 B35.2 B
Slightly volatile
Short and Long Term Debt Total49.8 B59.4 B41.7 B
Slightly volatile
Non Currrent Assets Other6.9 B6.6 BB
Slightly volatile
Common Stock Total Equity15.4 M16.2 M756.4 M
Slightly volatile
Short Term Debt5.2 B7.2 B4.3 B
Slightly volatile
Common Stock15.4 M16.2 M756.4 M
Slightly volatile
Long Term Debt Total50.1 B68 B40 B
Slightly volatile
Capital Surpluse15.8 B22.1 B12.8 B
Slightly volatile
Long Term Investments498.6 M304 M513.9 M
Pretty Stable
Non Current Liabilities Other19.7 B28.6 B14.2 B
Slightly volatile
Short and Long Term DebtB7.2 B5.1 B
Slightly volatile
Net Invested Capital74.5 B69.7 B56.4 B
Slightly volatile
Capital Stock14.4 M16.2 M17.6 M
Slightly volatile

AbbVie Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization9.1 B8.7 B3.5 B
Slightly volatile
Selling General AdministrativeB12.9 B7.5 B
Slightly volatile
Total Revenue33.8 B54.3 B32 B
Slightly volatile
Gross Profit25.2 B45.5 B23.8 B
Slightly volatile
Other Operating Expenses23.2 B36.9 B21.9 B
Slightly volatile
Operating Income9.4 B17.4 B8.8 B
Slightly volatile
EBIT8.8 B9.4 B8.3 B
Slightly volatile
Research Development5.4 BB5.1 B
Slightly volatile
EBITDA12 B18.1 B11.4 B
Slightly volatile
Cost Of Revenue8.7 B8.8 B8.2 B
Slightly volatile
Total Operating Expenses14.5 B28.1 B13.8 B
Slightly volatile
Income Before Tax7.3 B6.2 B6.8 B
Slightly volatile
Net Income6.3 B4.9 B5.9 B
Slightly volatile
Net Income Applicable To Common Shares14.3 B13.6 BB
Slightly volatile
Net Income From Continuing Ops6.9 B4.9 B5.9 B
Slightly volatile
Non Recurring553.6 M801.5 M493.5 M
Slightly volatile
Interest Income567 M540 M499.1 M
Slightly volatile
Reconciled Depreciation5.9 B8.7 B3.6 B
Slightly volatile
Selling And Marketing Expenses1.9 B2.3 B1.4 B
Slightly volatile

AbbVie Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation428.3 M747 M406.8 M
Slightly volatile
Free Cash Flow12 B22.1 B11.4 B
Slightly volatile
Begin Period Cash Flow8.9 B9.2 B8.7 B
Slightly volatile
Depreciation9.1 B8.7 B3.6 B
Slightly volatile
Capital Expenditures611.5 M777 M566.8 M
Slightly volatile
Total Cash From Operating Activities12.6 B22.8 B12 B
Slightly volatile
Net Income6.3 B4.9 B5.9 B
Slightly volatile
End Period Cash Flow9.8 B12.8 B9.6 B
Slightly volatile
Change To Netincome3.4 BB2.6 B
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.395.04414.2199
Pretty Stable
Dividend Yield0.02890.03850.0345
Slightly volatile
Days Sales Outstanding80.5574.958173.7154
Slightly volatile
Free Cash Flow Yield0.0650.08050.0803
Very volatile
Operating Cash Flow Per Share13.5612.9187.6193
Slightly volatile
Stock Based Compensation To Revenue0.00980.01380.0122
Slightly volatile
EV To Sales4.025.90154.9628
Slightly volatile
Free Cash Flow Per Share13.112.47857.2677
Slightly volatile
ROIC0.210.19480.1932
Slightly volatile
Inventory Turnover2.032.1424.1152
Slightly volatile
Net Income Per Share2.82.75063.5165
Slightly volatile
Days Of Inventory On Hand17917097.2327
Slightly volatile
Payables Turnover2.262.38075.7629
Slightly volatile
Sales General And Administrative To Revenue0.280.260.2538
Slightly volatile
Research And Ddevelopement To Revenue0.130.12950.1614
Very volatile
Cash Per Share5.07.24896.1668
Slightly volatile
POCF Ratio13.8911.996512.8027
Very volatile
Interest Coverage14.2810.440418.7944
Slightly volatile
Payout Ratio2.282.16721.0382
Slightly volatile
PFCF Ratio15.0412.41913.8388
Very volatile
Days Payables Outstanding16115378.906
Slightly volatile
Income Quality4.914.67722.2496
Slightly volatile
EV To Operating Cash Flow11.9814.035614.7755
Very volatile
PE Ratio59.1656.341128.244
Slightly volatile
Return On Tangible Assets0.09870.10390.2214
Slightly volatile
EV To Free Cash Flow17.7914.529916.2822
Very volatile
Earnings Yield0.01690.01770.0469
Slightly volatile
Intangibles To Total Assets0.430.65250.5337
Slightly volatile
Current Ratio1.710.87211.565
Slightly volatile
Receivables Turnover4.054.86944.9951
Slightly volatile
Graham Number15.9819.043219.7131
Slightly volatile
Revenue Per Share32.2630.722920.1229
Slightly volatile
Interest Debt Per Share22.5734.532825.4065
Slightly volatile
Debt To Assets0.620.44080.5675
Pretty Stable
Enterprise Value Over EBITDA12.8917.714315.8965
Pretty Stable
Short Term Coverage Ratios5.753.17615.3801
Pretty Stable
Price Earnings Ratio59.1656.341128.244
Slightly volatile
Operating Cycle132245162
Very volatile
Days Of Payables Outstanding16115378.906
Slightly volatile
Dividend Payout Ratio2.282.16721.0382
Slightly volatile
Price To Operating Cash Flows Ratio13.8911.996512.8027
Very volatile
Price To Free Cash Flows Ratio15.0412.41913.8388
Very volatile
Pretax Profit Margin0.110.11510.226
Slightly volatile
Ebt Per Ebit0.340.35871.2091
Very volatile
Operating Profit Margin0.310.32080.2824
Very volatile
Long Term Debt To Capitalization0.720.83440.8762
Very volatile
Total Debt To Capitalization0.730.85150.8842
Very volatile
Return On Capital Employed0.210.17990.1906
Slightly volatile
Ebit Per Revenue0.310.32080.2824
Very volatile
Quick Ratio1.260.63351.1602
Pretty Stable
Net Income Per E B T0.70.77810.8673
Pretty Stable
Cash Ratio0.520.33860.6389
Very volatile
Cash Conversion Cycle10192.044192.1921
Slightly volatile
Operating Cash Flow Sales Ratio0.280.42050.352
Slightly volatile
Days Of Inventory Outstanding17917097.2327
Slightly volatile
Days Of Sales Outstanding80.5574.958173.7154
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.750.9660.9273
Pretty Stable
Cash Flow Coverage Ratios0.330.38460.3143
Pretty Stable
Fixed Asset Turnover7.610.88769.37
Slightly volatile
Price Cash Flow Ratio13.8911.996512.8027
Very volatile
Enterprise Value Multiple12.8917.714315.8965
Pretty Stable
Debt Ratio0.620.44080.5675
Pretty Stable
Cash Flow To Debt Ratio0.330.38460.3143
Pretty Stable
Price Sales Ratio3.395.04414.2199
Pretty Stable
Return On Assets0.03430.03610.099
Slightly volatile
Asset Turnover0.570.40320.5265
Slightly volatile
Net Profit Margin0.08510.08950.1906
Slightly volatile
Gross Profit Margin0.60.83840.7398
Slightly volatile

AbbVie Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap74 B118 B111 B
Slightly volatile
Enterprise Value50.9 B57.3 B62.4 B
Slightly volatile

AbbVie Fundamental Market Drivers

Forward Price Earnings14.5773
Cash And Short Term Investments12.8 B

AbbVie Upcoming Events

2nd of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
2nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About AbbVie Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include AbbVie income statement, its balance sheet, and the statement of cash flows. AbbVie investors use historical funamental indicators, such as AbbVie's revenue or net income, to determine how well the company is positioned to perform in the future. Although AbbVie investors may use each financial statement separately, they are all related. The changes in AbbVie's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AbbVie's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on AbbVie Financial Statements. Understanding these patterns can help to make the right decision on long term investment in AbbVie. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-3.3 B-3.5 B
Total Revenue54.3 B33.8 B
Cost Of Revenue8.8 B8.7 B
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.26  0.28 
Research And Ddevelopement To Revenue 0.13  0.13 
Capex To Revenue(0.01)(0.01)
Revenue Per Share 30.72  32.26 
Ebit Per Revenue 0.32  0.31 

Pair Trading with AbbVie

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AbbVie position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AbbVie will appreciate offsetting losses from the drop in the long position's value.

Moving together with AbbVie Stock

  0.85EOLS Evolus Inc Financial Report 14th of May 2024 PairCorr

Moving against AbbVie Stock

  0.45LPTX Leap Therapeutics Financial Report 20th of May 2024 PairCorr
The ability to find closely correlated positions to AbbVie could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AbbVie when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AbbVie - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AbbVie Inc to buy it.
The correlation of AbbVie is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AbbVie moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AbbVie Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AbbVie can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether AbbVie Inc is a strong investment it is important to analyze AbbVie's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AbbVie's future performance. For an informed investment choice regarding AbbVie Stock, refer to the following important reports:
Check out the analysis of AbbVie Correlation against competitors.
Note that the AbbVie Inc information on this page should be used as a complementary analysis to other AbbVie's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for AbbVie Stock analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Money Managers
Screen money managers from public funds and ETFs managed around the world
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Stocks Directory
Find actively traded stocks across global markets
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Valuation
Check real value of public entities based on technical and fundamental data
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Is AbbVie's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AbbVie. If investors know AbbVie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AbbVie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.67)
Dividend Share
5.99
Earnings Share
2.71
Revenue Per Share
30.723
Quarterly Revenue Growth
(0.05)
The market value of AbbVie Inc is measured differently than its book value, which is the value of AbbVie that is recorded on the company's balance sheet. Investors also form their own opinion of AbbVie's value that differs from its market value or its book value, called intrinsic value, which is AbbVie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AbbVie's market value can be influenced by many factors that don't directly affect AbbVie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AbbVie's value and its price as these two are different measures arrived at by different means. Investors typically determine if AbbVie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AbbVie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.